Acute Kidney Injury
Part of NephTimes
Opinions differ on the use of no anticoagulation versus regional citrate anticoagulation for treatment of AKI with CKRT. A baseline creatinine measurement from clinical trial enrollment may not be the best way to detect acute kidney injury. SGLT-2is are associated with reduced risk of mortality in patients with type 2 diabetes and acute kidney disease. Patients who have acute kidney injury while hospitalized face increased risk for morbidity and mortality after discharge. The FDA has granted a Humanitarian Device Exemption Approval Order to the Selective Cytopheretic Device Pediatric. Patients hospitalized with COVID-19 face increased risk for long-term adverse outcomes such as major adverse kidney events. Community-acquired acute kidney injury (CA-AKI) is AKI that develops outside of the hospital setting. More patients in the terlipressin group had a >30% improvement in serum creatinine from baseline than in the placebo group. Effective blood pressure control following AKI may have beneficial effects on outcomes. Examining the effect of SGLT2 inhibitors on biomarkers of tubular injury in patients with acute heart failure. The difference in risk between White and Black patients was driven by greater MI risk in Black versus White patients. Perioperative administration of acetaminophen and reduced AKI after cardiac surgery. For all outcomes, rates of health care utilization were higher in the dialysis-treated AKI survivor group than in controls. Patients with COVID-19 had the worst outcomes, with higher rates of death. The total incidence of AKI in this cohort was low (n=5/41). Thirty-seven percent of recipients experienced delayed graft function/ The cost per response of terlipressin plus albumin was lower than M&O+albumin and norepi+albumin. A >30% reduction in serum creatinine inpatients with hepatorenal syndrome treated with terlipressin. While COVID-19 is recognized as a typical syndrome of acute respiratory illness, it can also affect multiple organ ... According to Y. Diana Kwong, MD, and colleagues, there are few data available on the symptom burden and quality of life ...